



The Next Generation of Prosthetic Heart Valves

Guest Editor:

**Assoc. Prof. Dr. Hadi
Mohammadi**

Heart Valve Performance
Laboratory, School of Mechanical
Engineering, Faculty of Medicine,
University of British Columbia,
Okanagan, Kelowna, BC, Canada

Deadline for manuscript
submissions:

closed (10 November 2020)

Message from the Guest Editor

Mitral regurgitation is one of the most common forms of heart valve disorders and occurs when blood leaks back into the left atrium from the left ventricle during heart contraction. This is a result of an apposition failure between the valve leaflets from a functional or congenital cause.

Mechanical heart valves are used to replace diseased human heart valves in approximately 50% of cases. Bioprosthetic heart valves are used in the other 45% of cases. Pulmonary autograft valves and human cryopreserved homograft valves represent the remainder of implanted valves. Autografts and homografts exhibit excellent durability after implantation but are not readily available for all patients. Catheter-based, also known as transcatheter or percutaneous, heart valves have already had successful implantation into the aortic and pulmonary valve position and are commercially available.

This Special Issue will discuss all the concerns that are important to be taken into consideration for the design and development of the next generation of heart valve prostheses.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
X@Bioeng_MDPI